College of Nursing, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Dev Psychobiol. 2024 Nov;66(7):e22540. doi: 10.1002/dev.22540.
There is emerging evidence that the endocannabinoid system (ECS) plays a significant role in the pathophysiology of many psychiatric disorders, including attention deficit hyperactivity disorder (ADHD). Increasing evidence suggests that a number of neurobiological correlates between endogenous cannabinoid function and cognitive dysfunction are seen in ADHD, making the ECS a possible target for therapeutic interventions. Cannabis use and cannabis use disorder are more prevalent in individuals with ADHD, compared to the general population, and there is growing popular perception that cannabis is therapeutic for ADHD. However, the relationship between cannabis use and ADHD symptomology is poorly understood. Further understanding of the role of the ECS in ADHD pathophysiology and the molecular alterations that may be a target for treatment is needed. To further the science on this emerging area of research, this scoping review describes the preclinical and clinical evidence seeking to understand the relationship between the ECS and ADHD.
越来越多的证据表明，内源性大麻素功能和认知功能障碍之间存在许多神经生物学相关性，这在 ADHD 中可见一斑，这使得 ECS 成为治疗干预的一个可能靶点。与普通人群相比，ADHD 患者中更常见的是使用大麻和大麻使用障碍，而且越来越多的人认为大麻对 ADHD 具有治疗作用。然而，大麻使用与 ADHD 症状之间的关系尚不清楚。需要进一步了解 ECS 在 ADHD 病理生理学中的作用以及可能成为治疗靶点的分子改变。为了进一步推进这一新兴研究领域的科学研究，本范围综述描述了旨在了解 ECS 与 ADHD 之间关系的临床前和临床证据。
